S510-1201 Screening compound: N-[(1H-1,3-benzodiazol-2-yl)methyl]-3-[3-(1-methanesulfonylpyrrolidin-2-yl)-1,2,4-oxadiazol-5-yl]propanamide

S510-1201 Screening compound: N-[(1H-1,3-benzodiazol-2-yl)methyl]-3-[3-(1-methanesulfonylpyrrolidin-2-yl)-1,2,4-oxadiazol-5-yl]propanamide
S510-1201 Screening compound: N-[(1H-1,3-benzodiazol-2-yl)methyl]-3-[3-(1-methanesulfonylpyrrolidin-2-yl)-1,2,4-oxadiazol-5-yl]propanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound S510-1201
N-[(1H-1,3-benzodiazol-2-yl)methyl]-3-[3-(1-methanesulfonylpyrrolidin-2-yl)-1,2,4-oxadiazol-5-yl]propanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

S510-1201

Molecular Formula

C18H22N6O4S (C18 H22 N6 O4 S)

Compound Name

N-[(1H-1,3-benzodiazol-2-yl)methyl]-3-[3-(1-methanesulfonylpyrrolidin-2-yl)-1,2,4-oxadiazol-5-yl]propanamide

IUPAC name

N-[(1H-13-benzodiazol-2-yl)methyl]-3-[3-(1-methanesulfonylpyrrolidin-2-yl)-124-oxadiazol-5-yl]propanamide

SMILES

CS(N(CCC1)C1c1noc(CCC(NCc2nc(cccc3)c3[nH]2)=O)n1)(=O)=O

InChI

InChI=1S/C18H22N6O4S/c1-29(26,27)24-10-4-7-14(24)18-22-17(28-23-18)9-8-16(25)19-11-15-20-12-5-2-3-6-13(12)21-15/h2-3,5-6,14H,4,7-11H2,1H3,(H,19,25)(H,20,21)/t14-/m0/s1

InChI Key

INICGXUOBDYLPV-AWEZNQCLSA-N

MDL Number (MFCD)

MFCD31992159

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

418.48

Hydrogen Bond Acceptors Count

11.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

8.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

1.066

Distribution Coefficient, logD

1.066

Water Solubility, LogSw

-2.22

Polar Surface Area

108.375

Acid Dissociation Constant (pKa)

12.34

Base Dissociation Constant (pKb)

4.58

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

44.44

S510-1201 in Drug Discovery

Included in Screening Libraries

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

KRAS-Targeted Library (16000 compounds)

PPI Helix Turn 3D-Mimetics Library (71298 compounds)

PPI Inhibitors Tripeptide Mimetics (23972 compounds)

Protein-Protein Interaction Library (218420 compounds)

Beyond the Flatland Library sp3 enriched (92988 compounds)

Peptidomimetic Library (37031 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Digestive system
  • Respiratory tract
  • Otorhinolaryngologic
Targets:
  • Kinases
Mechanism of action:
  • PPI modulators
  • PPI modulators
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics
  • Mimetics
  • Cyclic compounds
  • Mimetics

References: we are preparing a list of scientific research reports with S510-1201 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound S510-1201?
Check Price and Availability of S510-1201, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of S510-1201 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for S510-1201
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for S510-1201
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of S510-1201 available by request